Anti-FGF2 approaches as a strategy to compensate resistance to anti-VEGF therapy: long-pentraxin 3 as a novel antiangiogenic FGF2-antagonist.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  European Cytokine Network

• Publication date

  2009-12-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1684/ecn.2009.0175PMID 20167562
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Targeting Inflammatory Pathways for Prevention and Therapy of Cancer: Short-Term Friend, Long-Term Foe

  2009cited by this paper
• Resistance to EGF-R (erbB-1) and VEGF-R modulating agents.

  2009cited by this paper
• Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis.

  2009cited by this paper
• Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis.

  2009cited by this paper
• Inflammatory cells and chemokines sustain FGF2-induced angiogenesis.

  2009cited by this paper
• Targeting Angiogenesis from Premalignancy to Metastases

  2009cited by this paper
• Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited.

  2009cited by this paper
• Combinatory inhibition of VEGF and FGF2 is superior to solitary VEGF inhibition in an in vitro model of RPE-induced angiogenesis

  2009cited by this paper
• How well do angiogenesis inhibitors work? Biomarkers of response prove elusive.

  2009cited by this paper
• The long pentraxin PTX3 as a prototypic humoral pattern recognition receptor: interplay with cellular innate immunity

  2009cited by this paper
• Antiangiogenesis research is booming, as questions and studies proliferate.

  2009cited by this paper
• Structural Characterization of PTX3 Disulfide Bond Network and Its Multimeric Status in Cumulus Matrix Organization*

  2008cited by this paper
• Antiviral Activity of the Long Chain Pentraxin PTX3 against Influenza Viruses1

  2008cited by this paper
• Tumor angiogenesis.

  2008cited by this paper
• Binding of the Long Pentraxin PTX3 to Factor H: Interacting Domains and Function in the Regulation of Complement Activation1

  2008cited by this paper
• Antiangiogenics and radiotherapy

  2008cited by this paper
• Myeloid cell trafficking and tumor angiogenesis.

  2007cited by this paper
• The zebrafish/tumor xenograft angiogenesis assay

  2007cited by this paper
• Fibroblast growth factors/fibroblast growth factor receptors as targets for the development of anti-angiogenesis strategies.

  2007cited by this paper
• Combination angiostatic therapy completely inhibits ocular and tumor angiogenesis

  2007cited by this paper
• Angiogenesis: an organizing principle for drug discovery?

  2007cited by this paper
• Radiation therapy plus angiogenesis inhibition with bevacizumab: rationale and initial experience.

  2007cited by this paper
• Role of the soluble pattern recognition receptor PTX3 in vascular biology

  2007cited by this paper
• PTX3 interacts with inter-alpha-trypsin inhibitor: implications for hyaluronan organization and cumulus oophorus expansion.

  2007cited by this paper
• The discovery of basic fibroblast growth factor/fibroblast growth factor-2 and its role in haematological malignancies.

  2007cited by this paper
• Pentraxins in Innate Immunity: From C-Reactive Protein to the Long Pentraxin PTX3

  2007cited by this paper
• Sorafenib in advanced clear-cell renal-cell carcinoma.

  2007cited by this paper
• Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.

  2007cited by this paper
• The rationale for the combination of selective EGFR inhibitors with cytotoxic drugs and radiotherapy.

  2007cited by this paper
• Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma.

  2006cited by this paper
• Interaction of C1q with IgG1, C-reactive protein and pentraxin 3: mutational studies using recombinant globular head modules of human C1q A, B, and C chains.

  2006cited by this paper
• Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial.

  2006cited by this paper
• Identification of an Antiangiogenic FGF2-binding Site in the N Terminus of the Soluble Pattern Recognition Receptor PTX3*

  2006cited by this paper
• Pathogen-derived immunomodulatory molecules: future immunotherapeutics?

  2006cited by this paper
• Drug Insight: vascular disrupting agents and angiogenesis—novel approaches for drug delivery

  2006cited by this paper
• Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.

  2006cited by this paper
• Structure and function of the long pentraxin PTX3 glycosidic moiety: fine-tuning of the interaction with C1q and complement activation.

  2006cited by this paper
• Regulating angiogenesis at the level of PtdIns‐4,5‐P2

  2006cited by this paper
• The tissue pentraxin PTX3 limits C1q‐mediated complement activation and phagocytosis of apoptotic cells by dendritic cells

  2006cited by this paper
• Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility.

  2005cited by this paper
• Complexity and complementarity of outer membrane protein A recognition by cellular and humoral innate immunity receptors.

  2005cited by this paper
• A Secretory-type Protein, Containing a Pentraxin Domain, Interacts with an A-type K+ Channel*

  2005cited by this paper
• Human renal epithelial cells produce the long pentraxin PTX3.

  2005cited by this paper
• Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis.

  2005cited by this paper
• Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors.

  2005cited by this paper
• Expression of keratinocyte growth factor/fibroblast growth factor‐7 and its receptor in human lung cancer: correlation with tumour proliferative activity and patient prognosis

  2004cited by this paper
• Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

  2004cited by this paper
• Prognostic Significance of the Long Pentraxin PTX3 in Acute Myocardial Infarction

  2004cited by this paper
• Selective recognition of fibroblast growth factor-2 by the long pentraxin PTX3 inhibits angiogenesis.

  2004cited by this paper
• PTX3 function as an opsonin for the dectin‐1‐dependent internalization of zymosan by macrophages

  2004cited by this paper
• Evolution of the Fgf and Fgfr gene families.

  2004cited by this paper
• PTX3 plays a key role in the organization of the cumulus oophorus extracellular matrix and in in vivo fertilization

  2004cited by this paper
• Pentraxin 3, a non-redundant soluble pattern recognition receptor involved in innate immunity.

  2003cited by this paper
• Angiogenesis: Tumorigenesis and the angiogenic switch

  2003cited by this paper
• The Long Pentraxin Ptx3 Is Synthesized in IgA Glomerulonephritis and Activates Mesangial Cells 1

  2003cited by this paper
• Biochemical and functional characterization of the interaction between pentraxin 3 and C1q

  2003cited by this paper
• Recognition and clearance of apoptotic cells: a role for complement and pentraxins.

  2003cited by this paper
• The role of fibroblast growth factors in vascular development.

  2002cited by this paper
• Looking for a good endothelial address.

  2002cited by this paper
• Antiangiogenic therapy with interferon alpha for giant cell lesions of the jaws.

  2002cited by this paper
• Successful antiangiogenic therapy of giant cell angioblastoma with interferon alfa 2b: report of 2 cases.

  2002cited by this paper
• Effect of p53 Status on Tumor Response to Antiangiogenic Therapy

  2002cited by this paper
• Fibroblast Growth Factor-2 Determines Severity of Joint Disease in Adjuvant-Induced Arthritis in Rats

  2002cited by this paper
• VEGF, basic-FGF, and TGF-β in Crohn's disease and ulcerative colitis: a novel mechanism of chronic intestinal inflammation

  2001cited by this paper
• Angiogenesis: regulators and clinical applications.

  2001cited by this paper
• Fibroblast growth factor-2 antagonist activity and angiostatic capacity of sulfated Escherichia coli K5 polysaccharide derivatives.

  2001cited by this paper
• Paracrine and autocrine effects of fibroblast growth factor-4 in endothelial cells

  2001cited by this paper
• Basic fibroblast growth factor in asthma: measurement in bronchoalveolar lavage fluid basally and following allergen challenge.

  2001cited by this paper
• Modulation of tumor angiogenesis by conditional expression of fibroblast growth factor-2 affects early but not established tumors.

  2001cited by this paper
• Two distinct signalling pathways are involved in FGF2-stimulated proliferation of choriocapillary endothelial cells: A comparative study with VEGF

  2001cited by this paper
• PTX3 in small-vessel vasculitides: an independent indicator of disease activity produced at sites of inflammation.

  2001cited by this paper
• PTX3, A prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans.

  2000cited by this paper
• The long pentraxin PTX3 binds to apoptotic cells and regulates their clearance by antigen-presenting dendritic cells.

  2000cited by this paper
• A Broad Spectrum Secreted Chemokine Binding Protein Encoded by a Herpesvirus

  2000cited by this paper
• Identification of a Gammaherpesvirus Selective Chemokine Binding Protein That Inhibits Chemokine Action

  2000cited by this paper
• Angiogenesis in cancer and other diseases

  2000cited by this paper
• Antiangiogenic Therapy of a Recurrent Giant Cell Tumor of the Mandible With Interferon Alfa-2a

  1999cited by this paper
• Interferon-alpha-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule.

  1999cited by this paper
• Vascular endothelial growth factor C induces angiogenesis in vivo.

  1998cited by this paper
• Fibroblast Growth Factor-2 (FGF-2) Induces Vascular Endothelial Growth Factor (VEGF) Expression in the Endothelial Cells of Forming Capillaries: An Autocrine Mechanism Contributing to Angiogenesis

  1998cited by this paper
• The codependence of angiogenesis and chronic inflammation

  1997cited by this paper
• Multimer Formation and Ligand Recognition by the Long Pentraxin PTX3

  1997cited by this paper
• Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenes

  1997cited by this paper
• New model for the study of angiogenesis and antiangiogenesis in the chick embryo chorioallantoic membrane: the gelatin sponge/chorioallantoic membrane assay.

  1997cited by this paper
• Cloning of mouse ptx3, a new member of the pentraxin gene family expressed at extrahepatic sites.

  1996cited by this paper
• Receptor Specificity of the Fibroblast Growth Factor Family*

  1996cited by this paper
• Basic fibroblast growth factor overexpression in endothelial cells: an autocrine mechanism for angiogenesis and angioproliferative diseases.

  1996cited by this paper
• The interaction of C-reactive protein and serum amyloid P component with nuclear antigens.

  1996cited by this paper
• Structure and function of the pentraxins.

  1995cited by this paper
• Basic fibroblast growth factor upregulates the expression of vascular endothelial growth factor in vascular smooth muscle cells. Synergistic interaction with hypoxia.

  1995cited by this paper
• Fibroblast Growth Factor-2 Can Mediate Cell Attachment by Linking Receptors and Heparan Sulfate Proteoglycans on Neighboring Cells (*)

  1995cited by this paper
• The acute phase response.

  1994cited by this paper
• The major acute phase reactants: C-reactive protein, serum amyloid P component and serum amyloid A protein.

  1994cited by this paper
• Inducible expression of PTX3, a new member of the pentraxin family, in human mononuclear phagocytes.

  1994cited by this paper
• Basic fibroblast growth factor in the early human burn wound.

  1994cited by this paper
• TSG-14, a tumor necrosis factor- and IL-1-inducible protein, is a novel member of the pentaxin family of acute phase proteins.

  1993cited by this paper
• Interleukin-1-inducible genes in endothelial cells. Cloning of a new gene related to C-reactive protein and serum amyloid P component.

  1992cited by this paper
• Distinct phosphotyrosines on a growth factor receptor bind to specific molecules that mediate different signaling pathways.

  1992cited by this paper
• What is the evidence that tumors are angiogenesis dependent?

  1990cited by this paper
• Acute‐phase response of human hepatocytes: Regulation of acute‐phase protein synthesis by interleukin‐6

  1990cited by this paper

• Predictive value of serum HIF-1α/HIF-2α and YKL-40 levels for vascular invasion and prognosis of follicular thyroid cancer

  2024cites this paper
• Havoc in harmony: Unravelling the intricacies of angiogenesis orchestrated by the tumor microenvironment.

  2024cites this paper
• Gli1-mediated tumor cell-derived bFGF promotes tumor angiogenesis and pericyte coverage in non-small cell lung cancer

  2024cites this paper
• A novel drug specific mRNA biomarker predictor for selection of patients responding to dovitinib treatment of advanced renal cell carcinoma and other solid tumors

  2023cites this paper
• The Role of Pentraxin 3 in Gastrointestinal Cancers

  2023cites this paper
• Identification of essential genes and drug discovery in bladder cancer and inflammatory bowel disease via text mining and bioinformatics analysis.

  2023cites this paper
• Targeting endothelial permeability in the EPR effect.

  2023cites this paper
• Identi�cation of essential genes and drug discovery in bladder cancer and in�ammatory bowel disease via text mining and bioinformatics analysis

  2022cites this paper
• Evolving therapeutic proteins to precisely kill cancer cells.

  2022cites this paper
• Pentraxin 3 acts as a functional effector of Akt/NF-κB signaling to modulate the progression and cisplatin-resistance in non-small cell lung cancer.

  2021cites this paper
• Fibroblast CEBPD/SDF4 axis in response to chemotherapy-induced angiogenesis through CXCR4

  2021cites this paper
• Role of bFGF in Acquired Resistance upon Anti-VEGF Therapy in Cancer

  2021cites this paper
• Peptide-Conjugated Nanoparticles as Targeted Anti-angiogenesis Therapeutic and Diagnostic in Cancer.

  2019cites this paper
• Plumbagin inhibits cancer stem-like cells, angiogenesis and suppresses cell proliferation and invasion by targeting Wnt/β-catenin pathway in endocrine resistant breast cancer.

  2019cites this paper
• Mechanisms of resistance to anti-angiogenic treatments

  2019cites this paper
• An in vivo wound healing model for the characterization of the angiogenic process and its modulation by pharmacological interventions

  2019cites this paper
• Inhibitors of corneal inflammation and angiogenesis : Prospectives and challenges

  2019cites this paper
• Exploring the Extracellular Regulation of the Tumor Angiogenic Interaction Network Using a Systems Biology Model

  2019cites this paper
• Imbalance between angiogenic and anti-angiogenic factors in sera from patients with large-vessel vasculitis.

  2019cites this paper
• Redundant angiogenic signaling and tumor drug resistance.

  2018cites this paper
• Imatinib Ameliorated Retinal Neovascularization by Suppressing PDGFR-α and PDGFR-β

  2018cites this paper
• Influence of Strontium on Vascular Endothelial Growth Factor and Fibroblast Growth Factor 2 Expression in Rat Chondrocytes Cultured In Vitro

  2018cites this paper
• Microarray analysis for delineating the gene expression in biopsies of gastrocnemius muscle of patients with chronic critical limb ischaemia compared with non-ischaemic controls.

  2018cites this paper
• Synergistic Activity for Natural and Synthetic Inhibitors of Angiogenesis Induced by Murine Sarcoma L-1 and Human Kidney Cancer Cells.

  2017cites this paper
• Clinical Research and Practice

  2017cites this paper
• Prognostic Value of Basic Fibroblast Growth Factor (bFGF) in Lung Cancer: A Systematic Review with Meta-Analysis

  2016cites this paper
• Construction of a disulfide‐stabilized diabody against fibroblast growth factor‐2 and the inhibition activity in targeting breast cancer

  2016cites this paper
• Latest Results for Anti-Angiogenic Drugs in Cancer Treatment.

  2016cites this paper
• The Dual Complexity of PTX3 in Health and Disease: A Balancing Act?

  2016cites this paper
• Nucleolin Targeting Impairs the Progression of Pancreatic Cancer and Promotes the Normalization of Tumor Vasculature.

  2016cites this paper
• FGF2-mediated reciprocal tumor cell-endothelial cell interplay contributes to the growth of chemoresistant cells: a potential mechanism for superficial bladder cancer recurrence

  2016cites this paper
• Mechanisms of tumor microenvironment in promoting metastasis

  2016cites this paper
• Molecular and clinical significance of fibroblast growth factor 2 (FGF2 /bFGF) in malignancies of solid and hematological cancers for personalized therapies

  2016cites this paper
• A Phase II Study of PF‐03446962 in Patients with Advanced Malignant Pleural Mesothelioma. CCTG Trial IND.207

  2016cites this paper
• Escaping Antiangiogenic Therapy: Strategies Employed by Cancer Cells

  2016cites this paper
• Therapeutic uses of FGFs.

  2016cites this paper
• Design and application of peptide nanofibers for modulating angiogenesis

  2016cites this paper
• Utility of biomarkers in the prediction of oncologic outcome after radical cystectomy for squamous cell carcinoma.

  2015cites this paper
• Role of fibroblast growth factor in squamous cell carcinoma of the bladder: prognostic biomarker and potential therapeutic target.

  2015cites this paper
• A long pentraxin-3-derived pentapeptide for the therapy of FGF8b-driven steroid hormone-regulated cancers

  2015cites this paper
• Molecular and clinical profiles of syndecan-1 in solid and hematological cancer for prognosis and precision medicine

  2015cites this paper
• The Initiation and Progression of Tail Regeneration in Northern House Gecko Hemidactylus Flaviviridis at Role of Fibroblast Growth Factor 2 (Fgf2)

  2015cites this paper
• Omics of Hereditary Breast Cancer

  2014cites this paper
• Early effects of dexamethasone and anti-VEGF therapy in an inflammatory corneal neovascularization model.

  2014cites this paper
• Antiangiogenic Agents in Natural Products for the Treatment of Gynecologic Disorders

  2014cites this paper
• Knockdown of the inflammatory factor pentraxin-3 suppresses growth and invasion of lung adenocarcinoma through the AKT and NF-kappa B pathways.

  2014cites this paper
• Fibroblast growth factor 2 involved in the pathogenesis of synovial chondromatosis of temporomandibular joint.

  2014cites this paper
• Chemoprevention of Esophageal Cancer with Black Raspberries, Their Component Anthocyanins, and a Major Anthocyanin Metabolite, Protocatechuic Acid

  2014cites this paper
• In search of breast cancer cell secretions with therapeutic and diagnostic value.

  2014cites this paper
• Pentraxin 3 as Biomarker

  2014cites this paper
• Long pentraxin‐3 as an epithelial–stromal fibroblast growth factor‐targeting inhibitor in prostate cancer

  2013cites this paper
• Pentraxin 3 (PTX3) inhibits plasma cell/stromal cell cross‐talk in the bone marrow of multiple myeloma patients

  2013cites this paper
• Extracellular matrix metalloproteinase inducer (EMMPRIN) expression correlates positively with active angiogenesis and negatively with basic fibroblast growth factor expression in epithelial ovarian cancer

  2013cites this paper
• Regorafenib (BAY 73–4506): Stromal and Oncogenic Multikinase Inhibitor with Potential Activity in Renal Cell Carcinoma

  2013cites this paper
• Inflammasomes in carcinogenesis and anticancer immune responses

  2012cites this paper
• Long Pentraxin 3/Tumor Necrosis Factor-Stimulated Gene-6 Interaction: A Biological Rheostat for Fibroblast Growth Factor 2–Mediated Angiogenesis

  2012cites this paper
• Emerging Agents in Renal Cell Carcinoma

  2012cites this paper
• The Thymidine Phosphorylase Inhibitor 5′-O-Tritylinosine (KIN59) Is an Antiangiogenic Multitarget Fibroblast Growth Factor-2 Antagonist

  2012cites this paper
• Modulation of angiogenesis by dietary phytoconstituents in the prevention and intervention of breast cancer.

  2012cites this paper
• Novel Therapies for Metastatic Renal Cell Carcinoma: Efforts to Expand beyond the VEGF/mTOR Signaling Paradigm

  2012cites this paper
• Novel molecular targets for the therapy of renal cell carcinoma.

  2012cites this paper
• Serum Amyloid A Protein in Clinical Cancer Diagnosis

  2012cites this paper
• Controlling escape from angiogenesis inhibitors

  2012cites this paper
• Regulation of Angiogenesis in Human Cancer via Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2)

  2012cites this paper
• Synthesis of a Heparan Sulfate Mimetic Library Targeting FGF and VEGF via Click Chemistry on a Monosaccharide Template

  2012cites this paper
• Interaction of clodronate with fibroblast growth factor 2 reduces FGF2-activity in endothelial cells.

  2011cites this paper
• E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models.

  2011cites this paper
• Anti-angiogenic peptides for cancer therapeutics.

  2011cites this paper
• Inhibition of tumor angiogenesis by antibodies, synthetic small molecules and natural products.

  2011cites this paper
• Pathogen Recognition by the Long Pentraxin PTX3

  2011cites this paper
• bFGF interaction and in vivo angiogenesis inhibition by self-assembling sulfonic acid-based copolymers

  2011cites this paper
• Pentraxin 3 as a Novel Marker in Cardiovascular Diseases?

  2011cites this paper
• Pentraxins and atherosclerosis: the role of PTX3.

  2011cites this paper
• Long Pentraxin-3 Inhibits FGF8b-Dependent Angiogenesis and Growth of Steroid Hormone–Regulated Tumors

  2011cites this paper
• Escape mechanisms after antiangiogenic treatment, or why are the tumors growing again?

  2011cites this paper
• The Role of PTEN in Tumor Angiogenesis

  2011cites this paper
• Functional genomics of endothelial cells treated with anti-angiogenic or angiopreventive drugs

  2010cites this paper
• Oncotargets and Therapy Dovepress Epidermal Growth Factor, Latrophilin, and Seven Transmembrane Domain-containing Protein 1 Marker, a Novel Angiogenesis Marker

  year unknowncites this paper